Immuron Limited (IMRN)
| Previous Close | 2.5400 |
| Open | 2.5400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.4815 - 2.5400 |
| 52 Week Range | 1.4810 - 5.9600 |
| Volume | |
| Avg. Volume | 919,627 |
| Market Cap | 14.614M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings Date | Feb 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireImmuron Director Resignation
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other business interests. Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the Company. During Stephen’s tenure, Immuron launched Travelan® into the US
- GlobeNewswire
Immuron to host Live Virtual Event
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT. TRAVELAN® BOUND FOR PHASE 3 CLINICAL TRIALSExp
- GlobeNewswire
Immuron Travelan® sales continued strong growth
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcpMar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA FYTD Mar 2024 AUD$0.8 million up 35% on pcpMar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarterSales commenced on Walmart.com MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immu
